Among adults with COPD and type 2 inflammation, having a history of cardiovascular or metabolic disease did not change ...
Receiving dupilumab for 52 weeks lowered the risk for severe exacerbations vs. placebo in adults with COPD and type 2 ...
A clean indoor environment can help reduce exposure to pollution. “Use an air purifier with a HEPA filter and seal windows ...
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), today announced that it will be presenting two rapid-fire presentations at CHEST 2025, the annual meeting of the ...
Select your location to view local American Lung Association events and news near you.
The prisons watchdog has published its investigation into the death of a man who served at a prison in Peterborough. Stephen ...
Enrollment of 42 participants completed ahead of scheduleTopline data expected by early 2026COLUMBUS, Ohio--(BUSINESS WIRE)--Clarametyx Biosciences, Inc. (“Clarametyx”), a clinical-stage biotechnology ...
Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- ...
AstraZeneca's hopes of a big new indication for respiratory drug Fasenra in chronic obstructive pulmonary disease (COPD) have been dashed by a negative phase 3 trial. The RESOLUTE study of IL-5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback